Claritev sees specialty drugs driving healthcare costs higher in 2027

• Claritev's October 22, 2026, analysis identifies compounding pressures on healthcare costs heading into 2027, led by specialty drugs beyond GLP-1s.
• Employer healthcare costs rose nearly 8% in 2026, the steepest increase in over a decade; pharmacy spending climbed close to 15%.
• Chronic and mental health conditions account for roughly 90% of U.S. healthcare spending, underscoring the need for earlier intervention.
• Provider consolidation is increasing negotiating leverage and reimbursement rates, while clinical workforce costs remain a persistent source of upward pressure.
• AI is emerging as a cost factor as hospitals optimize billing; payers use it to sharpen claims adjudication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Claritev Corporation published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.